CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Pemetrexed +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00868192
NCT00868192Phase 2Completed
CompareCT.gov

Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma

Washington University School of Medicine·interventional·Posted Mar 24, 2009·Updated Oct 20, 2014

In Brief

A Phase 2 clinical trial evaluating Pemetrexed and Bevacizumab for Ovarian Carcinoma and Primary Peritoneal Carcinoma. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if the combination of bevacizumab and pemetrexed have an effect on recurrent ovarian and primary peritoneal carcinoma by looking at progression and survival at 6 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Carcinoma, Primary Peritoneal Carcinoma
CountriesUnited States
CollaboratorsColumbia University

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 24, 2009
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 17.3 years ago

Interventions

Pemetrexeddrug

Bevacizumabdrug